European Archives - Page 1315 of 1401 - European Medical Journal

EMJ

Dr Jim Duthie, Our #EMJExpert, Answers Your Questions for Blue September

In support of Blue September, an annual campaign designed to raise global awareness for male related cancers, we invited world-renowned urologist Dr Jim…

EMJ

New approaches to molecular cancer therapeutics

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…

EMJ

The Patient Reported Opinions about Clinical Tolerability (PROACT)

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient…

EMJ

EURECCA international comparison of treatment patterns for non-metastatic breast cancer

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK…

EMJ

Results from the ETOP Lungscape Project: Multiplex mutation testing in NSCLC

At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the…

EMJ

The causes and consequences of tumour evolution and heterogeneity

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…

EMJ

Patient-centered partnership improve access to optimal standards of cancer care in Europe

European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation, representing 365 patient organisations in 40…

EMJ

ECC 2015: Press programme with updates on ‘Europe of Disparities in Cancer’

At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queen’s University Belfast, Belfast, UK, Richard Sullivan, MD, PhD, of King’s College…

EMJ

The discovery of new biomarkers for predicting outcomes in breast cancer

In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to…

EMJ

First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in…